PFIZER is set to pour US$100m
into expansion plans for its
Singapore Nutrition Plant,
responsible for the manufacture of
its products for infants and children.
The investment will see the plant
blow out in suze to 91,963 square
metres and will see its production
capacity double, and in turn
expand its market foothold in the
Asia Pacific region.
“Infant Formula is one of the
most stringently regulated
consumer products in the world,”
said Natale Ricciardi, senior vice
president of Pfizer and president of
Pfizer Global Manufacturing.
“Quality and compliance are
critically important aspects of the
Pfizer Global Manufacturing
Culture,” she added.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jul 10
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.